Company Overview

Lyell Immunopharma, Inc. is a clinical-stage biotechnology company focused on the discovery and development of next-generation cell therapies for patients with solid tumors. The company operates within the biotechnology and immuno-oncology industries, with a specific emphasis on overcoming T cell exhaustion and dysfunction, which are key limitations of current cell therapy approaches in solid cancers. Lyell’s core strategy is to engineer more durable and effective T cells through proprietary technologies that enhance cellular fitness and persistence in hostile tumor microenvironments.

The company’s primary revenue drivers are its internal clinical-stage cell therapy programs and strategic research collaborations, rather than product sales, as Lyell does not yet have commercialized therapies. Lyell primarily serves oncology patients through clinical trial participation and collaborates with large pharmaceutical partners to advance its technology. Founded in 2018, Lyell was established by leaders in cancer research and biotechnology and has since evolved from a platform-focused startup into a publicly traded company advancing multiple assets into clinical development.

Business Operations

Lyell’s operations are centered on research, development, and clinical advancement of engineered T cell therapies, with its business organized around proprietary technology platforms and product candidates rather than traditional commercial segments. The company’s lead programs include LYL797, a ROR1-targeted CAR T-cell therapy, and LYL845, a dual-targeting CAR T-cell therapy, both designed for solid tumor indications. Revenue is primarily derived from collaboration and license agreements, including upfront payments and research funding, alongside interest income, as the company remains pre-commercial.

Operations are conducted primarily in the United States, supported by internal research laboratories, process development capabilities, and clinical operations infrastructure. Lyell controls key enabling technologies focused on epigenetic reprogramming and transcriptional control of T cells. The company maintains strategic partnerships, most notably a collaboration with GlaxoSmithKline (GSK), which supports development and validation of Lyell’s technology platforms. Lyell operates without significant joint ventures and relies on wholly owned subsidiaries for operational activities.

Strategic Position & Investments

Lyell’s strategic direction centers on establishing a leadership position in solid tumor cell therapy, an area with high unmet medical need and limited clinical success to date. Growth initiatives focus on advancing internal programs through clinical proof-of-concept, expanding its technology platforms, and selectively entering collaborations that provide capital and validation without ceding core intellectual property. The company has invested heavily in manufacturing process innovation to improve scalability and consistency of autologous cell therapies.

Key investments include the continued development of its epigenetic and transcriptional control technologies, as well as the expansion of its clinical pipeline beyond initial lead assets. While Lyell has not completed large-scale acquisitions, it has integrated licensed technologies and research assets into its platform. The company’s involvement in emerging sectors includes synthetic biology-enabled cell engineering and next-generation immunotherapy approaches aimed at durability and resistance to exhaustion.

Geographic Footprint

Lyell Immunopharma is headquartered in the United States, with principal operations in California and Washington State, where it maintains research, development, and administrative facilities. These locations support its laboratory research, process development, and clinical operations. The company’s geographic footprint is primarily North American, reflecting its focus on U.S.-based clinical trials and regulatory engagement.

Internationally, Lyell’s presence is indirect and primarily driven through clinical trial sites, academic collaborations, and its strategic partnership with Europe-based pharmaceutical partners. While it does not maintain significant standalone international offices, its therapies are intended for global development, and its intellectual property strategy is designed to support future commercialization across North America, Europe, and other major oncology markets.

Leadership & Governance

Lyell was founded by prominent leaders in cancer research and biotechnology, most notably Richard D. Klausner and Robert Valamehr, who helped define the company’s scientific vision. The leadership team emphasizes a science-driven culture focused on rigorous clinical validation and long-term innovation in cell therapy. Governance is overseen by a board with experience in biotechnology, pharmaceuticals, and public company management, reflecting Lyell’s status as a publicly traded company.

Key executives include:

• Lynn Seely, M.D. – Chief Executive Officer
• Richard D. Klausner, M.D. – Founder and Chief Scientist
• Robert Valamehr, Ph.D. – President, Research and Development
• Michael A. White – Chief Financial Officer
• Andrew R. Behnam – Chief Operating Officer

The leadership’s strategic vision centers on translating cutting-edge immunology into clinically meaningful therapies, with disciplined capital allocation and a focus on long-term value creation. Where executive roles or titles have evolved over time, available public disclosures are consistent, though some role transitions may reflect normal governance updates typical of clinical-stage biotechnology companies.